$ECOR electroCore Announces Record Second Quarter 2022 Financial Results
Source: GlobeNewswire Inc.
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced second quarter 2022 financial results and provided an operational update.
Second Quarter 2022 and Recent Highlights
Posted revenue of $2.2 million, representing an increase of approximately 70% over second quarter 2021 and 14% sequentially;
Net cash used in operating activities was $3.2 million during the second quarter 2022 leaving approximately $26.6 million of cash and cash equivalents at June 30, 2022;
Announced gammaCore™ non-invasive vagus nerve stimulator (nVNS) selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) program; and
Announced exclusive license agreement with Teijin Limited (Teijin) for Japan.
News 
Market Data 
Discover 
